TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04184778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smaller tube size
Description: Comparing how tube size affect patient's experience of postoperative sore throat and hoarseness in men and women.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smaller tube size
Description: Comparing how tube size affect patient's experience of postoperative sore throat and hoarseness in men and women.
Study: NCT04309487

Intervention type: DIAGNOSTIC_TEST
Intervention: ShuntCheck
Description: The intervention is an FDA-cleared device utilizing a transcutaneous thermal convection to analyze shunt flow.
Study: NCT02669043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intravenous ketamine 0.5mg/kg over 40 minutes
Study: NCT02614690

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Univalve Split Cast of forearm fractures
Description: Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to Univalve Cast will have a cast that is split on only one side of the cast, this is known as univalve cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bivalve Split Cast of forearm fractures
Description: Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to Bivalve Cast will have a cast that is split on both sides of the cast, this is known as bivalve cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months.
Study: NCT05295394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir plus lamivudine
Description: Dolutegravir 50 mg QD plus lamivudine 300 mg QD
Study: NCT01919515

Intervention type: DEVICE
Group type: OTHER
Intervention: ZR Crown
Description: This is an esthetic primary molar crown.

Intervention type: DEVICE
Group type: OTHER
Intervention: Stainless Steel Crown
Description: This is a conventional stainless steel crown.
Study: NCT04317261

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Xpert Bladder Cancer Monitor (Xpert Monitor) test and assay of urinary metabolomics (gene expression of CRAT and SLC)
Description: Urine sample is evaluated for RNA and urinary metabolites
Study: NCT06069453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA) sodium salt and Hydeal-D
Description: intravesical solution containing Hyaluronic Acid (HA) sodium salt and Hydeal-D
Study: NCT01985646

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery treatment
Description: one staged pull-through left-colectomy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: anal dilation
Description: anal dilation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: colonic lavage
Description: colonic lavage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral probiotic
Description: oral probiotic
Study: NCT02622633

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Epidural Electrode
Description: Epidural electrode of high frequency (50Hz) stimulation in the dorsolateral prefrontal cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural Electrode
Description: Epidural electrode of high frequency (50Hz) stimulation in the dorsolateral prefrontal cortex.
Study: NCT04658732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Alprazolam , Gabapentin , Dexmedetomidine
Description: Patients will be allocated into one of the 3 groups: Alprazolam (A group), Gabapentin (G group) and Dexmedetomidine (D group) as control group. Alprazolam group (n=15): patients in this group will receive 0.25 mg Alprazolam (2 tablets of Xanax 0.125 mg manufactured by Pfizer). Gabapentin group (n=15): patients in this group will receive 600mg Gabapentin (2 capsules of Neurontin 300 mg manufactured by Pfizer).Control group (n=15): patients in this group will receive 2 tablets of multivitamin (Vitamax manufactured by GlaxoSmithKline S.A.E) as placebo to ensure blindness of the study. The study drug will be received 120 minutes before the operation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Alprazolam , Gabapentin , Dexmedetomidine
Description: Patients will be allocated into one of the 3 groups: Alprazolam (A group), Gabapentin (G group) and Dexmedetomidine (D group) as control group. Alprazolam group (n=15): patients in this group will receive 0.25 mg Alprazolam (2 tablets of Xanax 0.125 mg manufactured by Pfizer). Gabapentin group (n=15): patients in this group will receive 600mg Gabapentin (2 capsules of Neurontin 300 mg manufactured by Pfizer).Control group (n=15): patients in this group will receive 2 tablets of multivitamin (Vitamax manufactured by GlaxoSmithKline S.A.E) as placebo to ensure blindness of the study. The study drug will be received 120 minutes before the operation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Alprazolam , Gabapentin , Dexmedetomidine
Description: Patients will be allocated into one of the 3 groups: Alprazolam (A group), Gabapentin (G group) and Dexmedetomidine (D group) as control group. Alprazolam group (n=15): patients in this group will receive 0.25 mg Alprazolam (2 tablets of Xanax 0.125 mg manufactured by Pfizer). Gabapentin group (n=15): patients in this group will receive 600mg Gabapentin (2 capsules of Neurontin 300 mg manufactured by Pfizer).Control group (n=15): patients in this group will receive 2 tablets of multivitamin (Vitamax manufactured by GlaxoSmithKline S.A.E) as placebo to ensure blindness of the study. The study drug will be received 120 minutes before the operation.
Study: NCT01026675

Intervention type: PROCEDURE
Intervention: 50 g oral glucose challenge test - 75 g oral glucose tolerance test
Description: 50 g oral glucose challenge test at 6-13 weeks of gestation and 75 g oral glucose tolerance test at 24-28 weeks of gestation.
Study: NCT01355874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iferanserin
Description: 0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 14 days during double blind.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo ointment BID for 14 days during double blind.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iferanserin + Placebo
Description: 0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 7 days followed by placebo ointment BID for 7 days during the double blind.
Study: NCT02401971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPT-11
Description: Given Ivgtt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPT-11
Description: Given Ivgtt
Study: NCT03029819

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based Addiction Treatment
Description: Mindfulness-based Addiction Treatment (MBAT) consists of 8 weekly 2-hour sessions that teach mindfulness and cognitive-behavioral strategies for smoking cessation (Wetter et al., 2009).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Addiction Treatment
Description: Mindfulness-based Addiction Treatment (MBAT) consists of 8 weekly 2-hour sessions that teach mindfulness and cognitive-behavioral strategies for smoking cessation (Wetter et al., 2009).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iQuit Mindfully
Description: iQuit Mindfully involves text messages on each day between treatment sessions. The text messages provide mindfulness and cognitive-behavioral strategies and support for smoking cessation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help guide
Description: Self-help materials for smoking cessation are based on the Treating Tobacco Use and Dependence Clinical Practice Guideline (Fiore et al. Clinical practice guideline for treating tobacco use and dependence, 2008).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Help guide
Description: Self-help materials for smoking cessation are based on the Treating Tobacco Use and Dependence Clinical Practice Guideline (Fiore et al. Clinical practice guideline for treating tobacco use and dependence, 2008).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Description: Patch therapy (beginning the week before quit day) for participants who smoke \>10 cigarettes/day will consist of 4 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day will consist of 4 weeks of 14 mg patches and 2 weeks of 7 mg patches.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Patch therapy (beginning the week before quit day) for participants who smoke \>10 cigarettes/day will consist of 4 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day will consist of 4 weeks of 14 mg patches and 2 weeks of 7 mg patches.
Study: NCT02888236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 32731

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 32731 Placebo
Study: NCT03339947

Intervention type: OTHER
Intervention: Questionnaire
Study: NCT02332200

Intervention type: OTHER
Intervention: Physical Therapy
Description: Physical therapy will consist of standard physical therapy care for spondylolysis or spondylolisthesis.

Intervention type: OTHER
Intervention: Physical Therapy
Description: Physical therapy will consist of standard physical therapy care for spondylolysis or spondylolisthesis.
Study: NCT04522206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-op Multimodal analgesia (MMA) regimen + standard post-op oxycodone
Description: The study subjects will be assigned to the defined pre-op MMA regimen with standard postop oxycodone based pain control regimen given on an as needed basis. The treatment group outcomes will be compared to patients outside of the study including a historical control group (receiving only post-op pain regimen) prior to the implementation of the new regimen. The studied treatment group will receive within 3 hours before surgery an oral MMA regimen consisting of:~Acetaminophen 975 mg Celecoxib 200 mg Gabapentin 300 mg Oxycodone 10 mg Extended Release
Study: NCT02228525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selinexor (KPT-330)
Study: NCT04456582

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shear wave elastography
Description: The elastographic technique by ultrasound (USE), shear waves or shear wave elastography (SWE), quantitatively evaluates tissue stiffness by mapping the propagation of acoustic waves (shear waves), in a non-invasive manner and without emission of ionizing radiation. Their speeds are tracked by the ultrasound equipment after tissue deformation occurs, generated by pulses of acoustic radiation (ARFI) of the transducer itself. Assuming the correlation between tissue stiffness and increased acoustic propagation speeds, it is possible to describe mathematically the elasticity of tissues by measuring specific acoustic waves.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shear wave elastography
Description: The elastographic technique by ultrasound (USE), shear waves or shear wave elastography (SWE), quantitatively evaluates tissue stiffness by mapping the propagation of acoustic waves (shear waves), in a non-invasive manner and without emission of ionizing radiation. Their speeds are tracked by the ultrasound equipment after tissue deformation occurs, generated by pulses of acoustic radiation (ARFI) of the transducer itself. Assuming the correlation between tissue stiffness and increased acoustic propagation speeds, it is possible to describe mathematically the elasticity of tissues by measuring specific acoustic waves.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Shear wave elastography
Description: The elastographic technique by ultrasound (USE), shear waves or shear wave elastography (SWE), quantitatively evaluates tissue stiffness by mapping the propagation of acoustic waves (shear waves), in a non-invasive manner and without emission of ionizing radiation. Their speeds are tracked by the ultrasound equipment after tissue deformation occurs, generated by pulses of acoustic radiation (ARFI) of the transducer itself. Assuming the correlation between tissue stiffness and increased acoustic propagation speeds, it is possible to describe mathematically the elasticity of tissues by measuring specific acoustic waves.
Study: NCT03688711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: Glucagon analogue

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for dasiglucagon
Study: NCT01729897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Study: NCT01482650

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: supraglottic airway placement and use
Description: The investigators will place the device (Baska mask or LMA) according to a pre-defined protocol and monitor its performance intra and postoperatively.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: supraglottic airway placement and use
Description: The investigators will place the device (Baska mask or LMA) according to a pre-defined protocol and monitor its performance intra and postoperatively.
Study: NCT02749058

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Capsulectomy in Direct Anterior Total Hip Arthroplasty
Description: Surgical intervention in which the surgeon will perform anterior capsulectomy during total hip arthroplasty.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Capsulotomy in Direct Anterior Total Hip Arthroplasty
Description: Surgical intervention in which the surgeon will perform anterior capsulotomy during total hip arthroplasty. Surgeon will repair the joint capsule.
Study: NCT05249296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature based solution for stress reduction
Description: participation in nature activities: daily 30 min walking in nature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature based solution for stress reduction
Description: participation in nature activities: daily 30 min walking in nature
Study: NCT01898975

Intervention type: OTHER
Intervention: 500ml fluid loading
Description: Fluid loading to evaluate fluid responsiveness
Study: NCT00904228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placement of plastic cap during delivery room stabilization
Description: placement of plastic cap during delivery room stabilization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placement of routine cap during delivery room stabilization
Study: NCT03983902

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed cord clamping
Description: Delayed cord clamping will occur for up to 2 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical cord milking
Description: Umbilical cord milking will occur milking of the 30 cm of the cord from placental site to baby, at a speed of 5 cm/second, 3 times in preterm newborns, 4 times in term newborns.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate cord clamping
Description: Immediate cord clamping will occur in 20 seconds after birth.
Study: NCT03486899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: Specified dose on specified days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days.
Study: NCT02769611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruboxistaurin
Description: Dose escalation trial. 1st ten patients to receive 64 mg, next 10 patients to receive 128 mg, next 10 patients to receive 256 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruboxistaurin
Description: Dose escalation trial. 1st ten patients to receive 64 mg, next 10 patients to receive 128 mg, next 10 patients to receive 256 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruboxistaurin
Description: Dose escalation trial. 1st ten patients to receive 64 mg, next 10 patients to receive 128 mg, next 10 patients to receive 256 mg.
Study: NCT04447443

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic Fiber Supplement + loperamide hydrochloride capsule
Description: 2-week sequential supplementation with prebiotic fiber supplement (3.5g, twice a day).~The initial dose of loperamide hydrochloride capsules is 4 mg (2 capsules) followed by 2 mg/4 h if diarrhea persists.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin + loperamide hydrochloride capsule
Description: 2-week sequential supplementation with placebo of of maltodextrin (3.5g, twice a day).~The initial dose of loperamide hydrochloride capsules is 4 mg (2 capsules) followed by 2 mg/4 h if diarrhea persists.
Study: NCT03753217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: qCON Monitor
Description: supervision by qCON monitor of the depth of anesthesia
Study: NCT00111254

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microdermabrasion
Description: Treatment will consist of 3 passes in different directions (horizontal, vertical and oblique) with the microdermabrasion handpiece (Parisian Peel, Prestige model, medical microdermabrasion device).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microdermabrasion
Description: Treatment will consist of 3 passes in different directions (horizontal, vertical and oblique) with the microdermabrasion handpiece (Parisian Peel, Prestige model, medical microdermabrasion device).
Study: NCT02030275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXI-109
Description: surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: surgery.
Study: NCT03912220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: The experimental arm will investigate the effects of nicotinamide riboside on nerve degeneration and regeneration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo drug that looks like the experimental drug, nicotinamide riboside tablets.
Study: NCT03549611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multimodal Oral Drug Regimen
Description: Regimen of 4 pharmacologic agents that provides analgesia by acting on 4 different physiologic pain pathways

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen 975mg
Study: NCT01037205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAS181 dry powder, formulation F02
Description: 10 mg delivered dose DAS181 in clear HPMC #3 Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAS181 dry powder, formulation F02
Description: 10 mg delivered dose DAS181 in clear HPMC #3 Capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Respitose ML006 (DMV-Fonterra)
Description: Lactose monohydrate
Study: NCT03973138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: DME patients who were diagnosed through fundus manifestations and FFA examination were treated by intravitreal injections of ranibizumab (0.5mg Lucentis®; Genentech, South San Francisco, CA) under the pro re nata (PRN) treatment regimen. The retreatment were conducted if BCVA was reduced by 0.1 logarithm of the minimal angle of resolution (logMAR) value or more from maximum acuity or if OCT central subfield thickness was more than 300μm.
Study: NCT03888170

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03696277

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiation (SABR)
Description: SAbR treatment regimens including ≥25Gy x1 fraction, ≥12Gy x 3 fractions, or ≥8Gy x 5 fractions.
Study: NCT01421082

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung Volume Reduction Coil (LVRC) (PneumRx, Inc.)
Description: Lung Volume Reduction Coil (LVRC)
Study: NCT01222611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosamprenavir
Description: HAART including fosamprenavir boosted with ritonavir
Study: NCT00662493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor control retraining program
Description: Specific retraining of VMO activation in a low-load situation,and progressed to integrate more functional positions. Use of dual channel biofeedback was incorporated

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quadriceps strengthening program
Description: 4 exercises focused on quadriceps strengthening commencing at a resistance of 60% 1 repetition maximum. Each exercise was performed for 3 sets of 10 repetitions
Study: NCT05851690

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment of pilonidal sinus disease
Description: Advancement flap techniques in surgical treatment of pilonidal sinus disease.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment of pilonidal sinus disease
Description: Advancement flap techniques in surgical treatment of pilonidal sinus disease.
Study: NCT00714350

Intervention type: BEHAVIORAL
Intervention: New ICU Display Visualization
Study: NCT00487786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OGX-427
Description: OGX-427 injection at 200mg, 400mg, 600mg, 800mg or 1000mg once a week until withdrawn

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: injection - 75 mg/M2 IV on Day 1 every 21 days for cohorts 6 \& 7 only, together with appropriate dose of OGX-427 until withdrawn from study